Pyros and Anovo Partner to Elevate Care for Infantile Spasms
April 1, 2024
Pyros Pharmaceuticals works to elevate the standard of care for children with rare disease by pioneering treatment options like VIGPODER™ (vigabatrin), a breakthrough treatment for infantile spasms.
What is West syndrome?
Infantile spasms, sometimes called West syndrome, are a type of seizure that affects babies. Although symptoms usually begin to show when infants are between 4 and 7 months old, spasms can start any time in the first few years of life. Infantile spasms look like a sudden stiffening of the muscles and occur in short bursts of about one to two minutes at a time – and affected babies can experience up to 100 seizures per day. Children with infantile spasms require treatment quickly after the onset of spasms or there is a risk of negative effects on the development of the child’s brain.
Pyros Pharmaceuticals Partners with Anovo
Our team at Anovo would like to extend heartfelt congratulations to Pyros Pharmaceuticals for the launch of VIGPODER™ (vigabatrin). We are honored to be chosen as the exclusive distributor and specialty pharmacy for this innovative medication. We believe in the potential of VIGPODER™ and its capacity to make a meaningful difference in the lives of those affected by infantile spasms.
Related Posts
Why Exclusivity Matters: Redefining Patient-Centricity in Rare and Ultra-Rare Drug Commercialization
In the rare disease space, every patient story is deeply personal, and every barrier to access feels monumental. From navigating…
June 4, 2025
The Heart of Our Success: How Our HR Team Fuels Growth & Culture
At Anovo, we know that our success starts with our people. Behind every dedicated team member, every seamless patient experience,…
May 19, 2025
Investing in Training to Elevate Patient Care
At Anovo, we believe that exceptional patient support starts with a well-trained, knowledgeable team. As we continue to grow, we’ve…
April 1, 2025
